Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 StudyLisa Licitra, Robert I. Haddad, Makoto Tahara et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 32
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implicationsDeniz Can Güven, Sercan Aksoy, Burak Yasin Aktaş et al.|Future Oncology|2020Cited by 25
Evaluation of Sarcopenia As A Prognostic Biomarker in Locally Advanced Head and Neck Squamous Cell CarcinomaEnes Erul, Sercan Aksoy, Yakup Özbay et al.|Biomarkers in Medicine|2023Cited by 21